Treatment induced sustained T-cell responses among patients with melanoma and non-small cell lung cancer.
Health Professionals
Yale Research Highlights Unmet Needs for Patients With Melanoma Who Progress or Relapse After Immunotherapy Treatment
A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients after the treatment.
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III melanoma.
Treatment Practices in Metastatic Melanoma
Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.